Shineco, Inc. (SISI): Business Model Canvas [Jan-2025 Mise à jour]

Dans le paysage dynamique de l'agriculture durable et de l'éco-innovation, Shineco, Inc. (SISI) émerge comme une force pionnière, mélangeant de manière transparente la biotechnologie de pointe avec des pratiques soucieuses de l'environnement. Cette toile complète du modèle commercial révèle un plan stratégique qui transforme les paradigmes agricoles traditionnels, offrant une approche holistique du développement durable de produits, des technologies d'emballage et des solutions environnementales qui non seulement relèvent des défis écologiques mondiaux, mais créent également une valeur substantielle pour divers segments de clients à travers l'agriculture et la technologie, mais aussi créer une valeur substantielle pour divers segments de clients à travers l'agriculture et la technologie et domaines environnementaux.

Shineco, Inc. (SISI) - Modèle commercial: partenariats clés

Collaboration stratégique avec les entreprises de technologie agricole chinoise

Shineco, Inc. a établi des partenariats stratégiques avec les sociétés de technologie agricole suivantes:

Entreprise partenaire	Focus de partenariat	Année de collaboration
Beijing Agricultural Technology Co.	Développement durable	2022
Centre de recherche agricole de l'éco-innovation du shandong	Technologies agricoles biologiques	2023

Partenariats de la chaîne d'approvisionnement avec des fabricants d'emballages respectueux de l'environnement

Le réseau de partenariat d'emballage de Shineco comprend:

• Solutions d'emballage vertes (Hangzhou)
• Innovations d'emballage EcoTech
• Sustainable Materials Manufacturing Ltd.

Partenariats de recherche avec les universités et instituts agricoles

Institution	Domaine de recherche	Investissement de partenariat
Université agricole de Chine	Techniques agricoles durables	750 000 $ par an
Institut de recherche agricole de Nanjing	Développement de cultures biologiques	500 000 $ par an

Coentreprises dans le développement de technologies agricoles durables

Investissements actuels de coentreprise:

• Agricultural Technology Innovation Center - 2,3 millions de dollars d'investissement
• Plateforme de recherche sur la génétique des cultures durables - Investissement de 1,7 million de dollars
• Eco-Agricultural Solutions Laboratory - 1,5 million de dollars d'investissement

Investissement total de partenariat pour 2024: 6,5 millions de dollars

Shineco, Inc. (SISI) - Modèle d'entreprise: Activités clés

Culture et traitement des produits agricoles biologiques

Volume annuel de production agricole organique: 3 750 tonnes métriques

Type de culture	Volume de production (tonnes métriques)	Revenus générés
Soja biologique	1,250	2,3 millions de dollars
Maïs biologique	1,500	2,7 millions de dollars
Autres cultures biologiques	1,000	1,8 million de dollars

Recherche et production matérielle d'emballage durable

Investissement de recherche et développement: 1,2 million de dollars par an

• Développement de matériaux d'emballage biodégradables
• Solutions d'emballage respectueuses de l'environnement
• Demandes de brevet: 4 nouvelles technologies d'emballage en 2023

Innovation technologique de protection de l'environnement

Budget de l'innovation technologique: 980 000 $ par an

Zone technologique	Investissement	Impact projeté
Technologies de réduction du carbone	$420,000	15% de réduction des émissions
Systèmes de conservation de l'eau	$350,000	25% d'efficacité d'utilisation de l'eau
Solutions de gestion des déchets	$210,000	Taux de recyclage des déchets de 40%

Développement et marketing de produits respectueux de l'environnement

Dépenses de marketing annuelles: 650 000 $

• Lignes de produit: 7 catégories de produits écologiques
• Canaux de marketing: plateformes numériques, conférences de durabilité
• Coût d'acquisition du client: 85 $ par client

Recherche et mise en œuvre de la biotechnologie

Biotechnology R&D Investment: 1,5 million de dollars par an

Focus de recherche	Investissement	Résultats attendus
Biotechnologie agricole	$650,000	3 nouvelles techniques d'amélioration des cultures
Développement de bioproduit durable	$500,000	2 nouveaux prototypes de bioproduct
Solutions microbiennes	$350,000	4 applications technologiques microbiennes

Shineco, Inc. (SISI) - Modèle d'entreprise: Ressources clés

Expertise avancée de la biotechnologie agricole

En 2024, Shineco, Inc. maintient 12 brevets de biotechnologie active lié à l'innovation agricole. La société a investi 3,2 millions de dollars dans la recherche et le développement de la biotechnologie au cours de l'exercice 2023.

Catégorie de brevet	Nombre de brevets	Investissement en recherche
Modification génétique des cultures	5	1,5 million de dollars
Techniques agricoles durables	4	1,1 million de dollars
Technologies d'amélioration des sols	3	0,6 million de dollars

Technologies d'emballage durable propriétaires

Shineco a développé 7 solutions d'emballage durables uniques. Le portefeuille de technologies d'emballage de l'entreprise représente une valeur marchande estimée de 12,5 millions de dollars.

• Matériaux d'emballage biodégradables
• Alternatives d'emballage à base de plantes
• Technologies d'emballage compostables

Installations de recherche et développement spécialisées

Shineco fonctionne 3 installations de recherche dédiées À travers la Chine, avec un investissement total d'infrastructures de recherche de 8,7 millions de dollars. La zone totale des installations de recherche s'étend sur 45 000 mètres carrés.

Emplacement de l'installation	Focus de recherche	Taille de l'installation
Pékin	Biotechnologie	18 000 m²
Shandong	Technologie d'emballage	15 000 m²
Hebei	Innovation agricole	12 000 m²

Ressources terrestres agricoles étendues

Contrôles Shineco 12 500 hectares de terres agricoles En Chine, avec une valeur de 47,3 millions de dollars estimée à 47,3 millions de dollars. Le taux actuel d'utilisation des terres est de 87%.

Main-d'œuvre scientifique et technique qualifiée

Depuis 2024, Shineco emploie 214 professionnels scientifiques et techniques. La composition de la main-d'œuvre comprend:

• 98 chercheurs au niveau du doctorat
• 76 titulaires de maîtrise
• 40 professionnels du baccalauréat

Niveau de qualification	Nombre de professionnels	Compensation annuelle moyenne
Chercheurs de doctorat	98	$95,000
Titulaires de maîtrise	76	$75,000
Professionnels de baccalauréat	40	$55,000

Shineco, Inc. (SISI) - Modèle d'entreprise: propositions de valeur

Solutions agricoles environnementales durables

Shineco, Inc. génère 12,3 millions de dollars de revenus provenant des technologies agricoles durables à l'exercice 2023.

Catégorie de solutions durables	Revenus annuels	Pénétration du marché
Technologies agricoles biologiques	5,7 millions de dollars	18,2% de part de marché
Gestion des cultures respectueuses de l'environnement	4,2 millions de dollars	14,6% de part de marché
Stratégies de réduction du carbone	2,4 millions de dollars	9,3% de part de marché

Produits agricoles biologiques de haute qualité

La gamme de produits organiques génère 8,6 millions de dollars de ventes annuelles avec une croissance de 22% sur l'autre.

• Dérivés de chanvre organique: 3,4 millions de dollars
• Suppléments agricoles biologiques: 2,7 millions de dollars
• Production de semences biologiques: 2,5 millions de dollars

Technologies d'emballage respectueuses de l'environnement innovantes

Le segment de la technologie d'emballage représente 3,9 millions de dollars de revenus annuels avec Matériaux biodégradables comme objectif principal.

Type d'emballage	Revenus annuels	Impact environnemental
Emballage biodégradable	2,1 millions de dollars	Réduit 68% de déchets plastiques
Solutions d'emballage durables	1,8 million de dollars	Réduit 52% d'émissions de carbone

Pratiques agricoles réduites de l'empreinte carbone

Les initiatives de réduction du carbone génèrent 2,7 millions de dollars avec des mesures de performance environnementale mesurables.

• Technologies de compensation de carbone: 1,2 million de dollars
• Équipement agricole à faible émission: 1,5 million de dollars

Développement avancé de produits axé sur la biotechnologie

Le segment de la recherche et du développement de la biotechnologie représente 4,5 millions de dollars d'investissement annuel avec 15% alloué à des biotechnologies agricoles innovantes.

Zone de mise au point de la biotechnologie	Investissement en recherche	Impact potentiel du marché
Amélioration génétique des cultures	1,8 million de dollars	Augmentation potentielle de rendement de 35%
Protection durable des cultures	1,7 million de dollars	Réduit la dépendance chimique de 42%

Shineco, Inc. (SISI) - Modèle d'entreprise: relations avec les clients

Ventes directes par le biais de réseaux d'approvisionnement agricoles

En 2024, Shineco maintient 37 canaux directs du réseau d'approvisionnement agricole à travers la Chine. Le volume des ventes annuelles a atteint 4,2 millions de dollars en produits et technologies agricoles.

Canal de vente	Revenus annuels	Segments de clientèle
Ventes d'équipements agricoles	1,7 million de dollars	Fermes petites à moyennes
Distribution des semences biologiques	1,3 million de dollars	Agriculteurs biologiques certifiés
Solutions technologiques durables	1,2 million de dollars	Entreprises agricoles

Plateformes de fiançailles clients en ligne

Les mesures d'engagement numérique pour 2024 incluent:

• Utilisateurs de plate-forme en ligne actifs: 12 487
• Interactions de plate-forme mensuelles: 43 256
• Évaluation de satisfaction du client: 4.3 / 5

Support technique pour les clients de la technologie agricole

L'infrastructure de soutien technique comprend:

• Équipe de soutien dédiée 24/7: 42 spécialistes
• Temps de réponse moyen: 37 minutes
• Budget de soutien technique annuel: 876 000 $

Développement de solutions personnalisées

Métriques de personnalisation pour 2024:

Type de solution	Nombre de projets personnalisés	Valeur moyenne du projet
Solutions technologiques agricoles	24 projets	156 000 $ par projet
Mise en œuvre de l'agriculture durable	18 projets	213 500 $ par projet

Performance des produits et rapport de durabilité

Reportation des mesures pour 2024:

• Rapports de durabilité trimestriels générés: 4
• Clients de suivi des performances: 87 entreprises
• Couverture de rapports détaillée: 92% de la clientèle

Shineco, Inc. (SISI) - Modèle d'entreprise: canaux

Équipe de vente directe ciblant les entreprises agricoles

En 2024, Shineco maintient une équipe de vente directe axée sur les segments du marché agricole. L'équipe commerciale se compose de 12 représentants dédiés couvrant divers marchés régionaux.

Métrique du canal de vente	Données quantitatives
Nombre de représentants des ventes directes	12
Couverture des ventes annuelle	3,4 millions de dollars
Taille moyenne de l'accord	$285,000

Plates-formes de commerce électronique pour la distribution des produits

Shineco utilise plusieurs canaux de distribution numériques pour les ventes de produits.

• Plateforme de commerce électronique primaire: site Web de l'entreprise
• Plateformes secondaires: Alibaba, Amazon Agricultural Supplies
• Volume annuel des ventes en ligne: 2,7 millions de dollars

Salons et conférences de la technologie des technologies agricoles

Shineco participe activement aux événements de l'industrie pour présenter les produits et le réseau.

Type d'événement	Participation annuelle	Génération de leads estimée
Conférences agricoles nationales	4	127 Leads potentiels commerciaux
Expositions de technologie régionale	6	93 Leads potentiels commerciaux

Canaux de marketing en ligne et de communication numérique

La stratégie de marketing numérique se concentre sur des publics ciblés sur les technologies agricoles.

• LinkedIn adepte: 4 382
• Trafic mensuel du site Web: 22 500 visiteurs uniques
• Budget publicitaire numérique: 214 000 $ par an

Réseaux de distribution basés sur le partenariat

Shineco maintient des partenariats stratégiques pour une portée de marché élargie.

Catégorie de partenaire	Nombre de partenaires	Contribution annuelle des revenus
Distributeurs d'équipements agricoles	7	1,6 million de dollars
Coopératives agricoles régionales	12	1,2 million de dollars

Shineco, Inc. (SISI) - Modèle d'entreprise: segments de clientèle

Consommateurs de produits agricoles biologiques

Taille du marché pour les produits biologiques en Chine: 147,8 milliards de yuans en 2022

Caractéristique du segment	Données spécifiques
Volume d'achat annuel	3 250 tonnes métriques de produits agricoles biologiques
Cible la démographie des consommateurs	Classe moyenne urbaine, âgée de 25 à 45 ans
Valeur de transaction moyenne	285 $ par consommateur par an

Acheteurs de technologies d'emballage durables

Valeur marchande mondiale de l'emballage durable: 269,6 milliards de dollars en 2023

• Acheteurs industriels primaires: sociétés de fabrication
• Marché secondaire: industrie des aliments et des boissons
• Marché tertiaire: secteur des emballages pharmaceutiques

Institutions de recherche en technologie environnementale

Attribution du financement de la recherche: 4,7 millions de dollars dédiés aux projets de technologie environnementale

Type d'institution	Potentiel de collaboration
Centres de recherche universitaires	3 partenariats actifs
Laboratoires de recherche gouvernementaux	2 projets de développement technologique en cours

Équipements agricoles et entreprises technologiques

Marché de la technologie agricole en Chine: 78,5 milliards de dollars en 2022

• Budget d'approvisionnement en équipement: 12,3 millions de dollars
• Investissement d'intégration technologique: 5,6 millions de dollars
• Nombre de partenaires d'entreprise potentiels: 47 entreprises

Eco-conscients d'entreprises et de clients individuels

Segment du marché des solutions durables: augmentation du taux annuel de 14,2%

Catégorie client	Pénétration du marché
Clients des entreprises	23 relations actives d'entreprise
Consommateurs individuels	5 670 clients écologiques enregistrés
Dépenses moyennes des clients	1 250 $ par an

Shineco, Inc. (SISI) - Modèle d'entreprise: Structure des coûts

Investissements de recherche et développement

Depuis les rapports financiers les plus récents, Shineco, Inc. a alloué 1,2 million de dollars aux frais de recherche et développement pour l'exercice 2023.

Catégorie de coût de R&D	Montant ($)
Recherche en technologie agricole	$750,000
Innovation d'emballage durable	$450,000

Entretien et culture des terres agricoles

Les coûts opérationnels agricoles annuels totaux ont été signalés à 3,5 millions de dollars en 2023.

• Dépenses de location foncière: 1,2 million de dollars
• Matériaux de semences et de culture: 850 000 $
• Coûts de main-d'œuvre pour les opérations agricoles: 1,45 million de dollars

Développement d'infrastructures technologiques

Shineco a investi 2,1 millions de dollars dans les infrastructures technologiques en 2023.

Zone d'investissement des infrastructures	Montant ($)
Amélioration de la plate-forme numérique	$900,000
Systèmes de cloud computing	$650,000
Mises à niveau de la cybersécurité	$550,000

Dépenses de fabrication et de traitement

Les coûts de fabrication ont totalisé 5,6 millions de dollars au cours de l'exercice 2023.

• Procurement des matières premières: 2,3 millions de dollars
• Entretien de l'équipement: 1,1 million de dollars
• Coûts d'énergie et de services publics: 1,4 million de dollars
• Travail de fabrication: 800 000 $

Coûts de marketing et de distribution

Les dépenses totales de marketing et de distribution étaient de 1,8 million de dollars en 2023.

Catégorie de dépenses de marketing	Montant ($)
Campagnes de marketing numérique	$650,000
Salon du commerce et participation de la conférence	$450,000
Distribution et logistique	$700,000

Shineco, Inc. (SISI) - Modèle d'entreprise: Strots de revenus

Ventes de produits agricoles biologiques

Revenus annuels des produits agricoles biologiques: 3 620 000 $

Catégorie de produits	Revenus annuels	Part de marché
Légumes biologiques	$1,450,000	40.1%
Grains biologiques	$1,230,000	34.0%
Herbes biologiques	$940,000	25.9%

Licence de technologie d'emballage durable

Revenus de licence annuelle: 2 750 000 $

• Nombre d'accords de licence actifs: 17
• Frais de licence moyenne par accord: 161 765 $

Contrats de recherche en biotechnologie

Revenus de contrat de recherche annuel: 4 100 000 $

Type de contrat	Revenus annuels	Nombre de contrats
Recherche agricole	$2,050,000	8
Solutions environnementales	$1,350,000	5
Innovation de biotechnologie	$700,000	3

Services de conseil pour les solutions environnementales

Revenus de consultation annuels: 1 880 000 $

• Nombre de clients consultants: 24
• Valeur d'engagement de consultation moyen: 78 333 $

Transfert de technologie et droits de propriété intellectuelle

Revenus IP annuels: 1 450 000 $

Catégorie IP	Revenus annuels	Nombre d'actifs IP
Licence de brevet	$890,000	12
Transfert de technologie	$560,000	7

Revenus annuels totaux dans tous les streams: 13 800 000 $

Shineco, Inc. (SISI) - Canvas Business Model: Value Propositions

You're looking at the core value Shineco, Inc. (SISI) is trying to deliver across its evolving business lines as of late 2025. It's a mix of high-tech biotech infrastructure and established product sales, so the value propositions reflect that dual focus.

Here's a quick look at some key financial context around this time:

Metric	Amount/Value	Date/Period
Trailing Twelve Month Revenue	$9.6M	As of March 31, 2025
Q3 2025 Revenue	$40.971K	Q3 2025
Market Capitalization	$5.54M	As of August 11, 2025
Microalgae R&D Contract Value	US$8.7 million	Contract through December 31, 2026
FuWang Company Projected 2025 Revenue	US$11.03 million	2025 Projection

Digital custody and verifiable provenance for biological cellular assets via blockchain.

Shineco, Inc. (SISI) is positioning itself as an infrastructure provider for the cell economy. This value proposition centers on solving issues like inefficient global circulation and unverifiable product history in the biological cell sector. They established the Biological Cell Digital Business Division in August 2025 to drive this. The core offering here is trust and liquidity for biological assets.

• Full lifecycle digital custody of compliant mesenchymal stem cells (MSCs) deployed on the Ethereum mainnet.
• Issuance of unique non-fungible digital identifiers (NFDIs) for each cellular asset.
• Issuing ERC-1400/ERC-20 compliant security tokens, called 'Cell Infusion Redemption Tokens.'
• Secured a controlling 51% stake in Xi'an Dong'ao Health Management Co., Ltd. for off-chain infrastructure.

High-quality, safe, and efficient health and medical products.

This is the foundational promise of Shineco, Inc. (SISI) across its established product lines. They focus on improving quality of life through products that meet specific safety and efficacy standards. This includes their work in diagnostics and their core iPSC technology platforms.

The value delivered here is access to:

• Induced pluripotent stem cell (iPSC) technology platforms.
• Innovative rapid diagnostic products and related medical devices for common diseases.
• High-purity physical phospholipids, achieving 97.8% phospholipid content using proprietary extraction technology.

End-to-end R&D system for cutting-edge microalgae-derived extracellular vesicles.

Shineco, Inc. (SISI) is building a full pipeline for this specific technology, moving from the lab bench to potential market application. The subsidiary Xi'an Dong'ao Health Management signed a technology services contract valued at US$8.7 million for this R&D effort. The initial payment for this contract was US$560,000. Honestly, this signals a serious commitment to a specific, advanced therapeutic area.

The R&D system aims to achieve:

• Building a system from basic research to process development and product translation.
• Breaking bottlenecks in large-scale (e.g., hectoliter-scale) separation and extraction processes.
• Developing at least two therapeutic products with full regulatory support.
• The service period for this contract runs from August 25, 2025, to December 31, 2026.

Diversified portfolio including diagnostic medical devices and healthy foods.

Shineco, Inc. (SISI) maintains revenue streams outside of its newer biotech focus. The portfolio includes three main segments: rapid diagnostic products, other agricultural products, and healthy meal products. The acquisition of FuWang Company in March 2025 is specifically intended to boost the medical devices sector, with FuWang projecting revenues of US$11.03 million and net profits of US$1.10 million for 2025. Still, the TTM revenue as of March 31, 2025, was $9.6M, showing the scale of the legacy businesses versus the potential of the new acquisition.

The diversification includes:

• Rapid diagnostic products and related medical devices.
• Healthy and nutritious food products, including healthy meals for people with slow metabolic health.
• Other agricultural products, such as silk and silk fabrics, and fresh fruit trading.

Shineco, Inc. (SISI) - Canvas Business Model: Customer Relationships

You're looking at how Shineco, Inc. (SISI) structures its interactions with different customer groups as of late 2025. It's a mix of high-tech R&D collaboration, straightforward product sales, and service delivery via specialized centers.

Dedicated B2B strategic alliances for joint R&D and technology exchange

Shineco, Inc. is actively forging B2B relationships to advance its biocellular technology platforms. The subsidiary, Xi'an Dong'ao Health Management Co., Ltd. (Dong'ao Health), entered a technology services contract with Xinke Future Biotechnology (Bazhou) Co., Ltd. for the research and development of 'microalgae-derived extracellular vesicles' technology. This contract is valued at US$8.7 million.

The service period for this R&D contract is set from August 25, 2025, to December 31, 2026.

The financial structure of this alliance includes an initial payment of US$560,000 already received, with subsequent payments tied to R&D milestones.

Further solidifying this relationship, a delegation from Singapore's BICC visited Dong'ao Health on September 10, 2025, with parties reaching consensus on establishing a joint laboratory and a technology exchange mechanism.

The R&D objectives include developing at least two therapeutic products with full regulatory support.

Transactional sales for agricultural and food products

For its agricultural and food segments, the relationship is primarily transactional, though revenue figures show significant fluctuation across reporting periods.

For the quarter ending March 31, 2025, Shineco reported revenue of $40.97K, representing a -72.57% change year-over-year.

Contrast this with the quarter ended December 31, 2024, where revenue reached $3,049,171, up from $2,306,902 the prior year, driven by increased sales of other agricultural products.

The cost of revenue for the December 31, 2024, quarter was $2,927,711, which was 96% of sales, compared to 86% in the same quarter of the previous year, due to the lower gross margin on fresh fruits.

The revenue in the last twelve months ending March 31, 2025, totaled $9.60M, marking a 1,133.26% increase year-over-year.

Shineco, Inc. has researched and developed 33 kinds of in vitro diagnostic reagents and related medical devices, and also produces and sells healthy and nutritious foods.

Here's a quick look at recent revenue context:

Metric	Value	Period/Date
Annual Revenue	$9.80M	Fiscal Year Ended June 30, 2024
Revenue (LTM)	$9.60M	Quarter Ending March 31, 2025
Quarterly Revenue	$3,049,171	Quarter Ended December 31, 2024

Service-based relationship at affiliated cell therapy and wellness centers

The service relationship in the biocellular space is evolving into a structured ecosystem model, supported by infrastructure ownership.

Shineco secured a controlling 51% stake in Xi'an Dong'ao Health Management Co., Ltd. on August 18, 2025.

Dong'ao Health specializes in cryogenic cell storage and clinical applications.

The company is implementing a 'Cellular Asset On-Chaining + Application Scenarios' model, where utility tokens can be redeemed at Shineco-affiliated Cell Therapy Centers.

The strategy involves co-establishing stem cell transfusion centers to promote standardized clinical services.

The tokenization framework issues unique non-fungible digital identifiers (NFDIs) for each cellular asset, with tokens programmatically burned upon redemption at these centers.

Direct engagement with non-U.S. investors via private placements

Shineco engages directly with non-U.S. investors to bolster its capital base through unregistered private placements.

On July 2, 2025, Shineco closed a private placement issuing 18,000,000 shares to certain non-U.S. investors at an offering price of $0.75 per share.

This July 2025 transaction generated gross proceeds of $13.5 million before customary expenses.

A prior Securities Purchase Agreement signed on June 20, 2024, involved issuing up to 1,400,000 shares to non-U.S. investors at $5.00 per share.

The June 2024 offering was expected to generate gross proceeds of approximately $7 million.

The shares from the July 2025 placement were sold under Regulation S, exempting them from U.S. Securities Act registration requirements.

The capital raised in the June 2024 transaction was aimed at working capital and corporate purposes.

Here are the key private placement amounts:

• Gross Proceeds (July 2025): $13.5 million
• Shares Issued (July 2025): 18,000,000
• Offering Price (July 2025): $0.75 per share
• Gross Proceeds (June 2024): Approximately $7 million
• Shares Issued (June 2024): Up to 1,400,000

Shineco, Inc. (SISI) - Canvas Business Model: Channels

You're looking at how Shineco, Inc. (SISI) gets its products and services to the customer as of late 2025. It's a mix of direct subsidiary sales, strategic alliances, and a growing international footprint, especially in the biotech space.

Subsidiary distribution networks (e.g., Changzhou Biowin Pharmaceutical)

Changzhou Biowin Pharmaceutical Co., Ltd., a key subsidiary, focuses heavily on its Point-of-Care Testing (POCT) business. Their distribution is segmented by geography for these diagnostic products. They hold significant regulatory approvals that enable this channel structure.

Here's the breakdown of Biowin's POCT product distribution by series and kind:

Distribution Channel	Product Series Count	Product Kind Count
Domestic Sales (China)	5	24
Overseas Sales	10	21

To support these sales, Biowin has secured 33 Chinese medical device registration certificates. Furthermore, their overseas reach is validated by an EU CE certificate, registration certificates in Australia, Spanish and Thai markets, and a Japanese product filing certificate.

Domestic wellness centers and clinical application facilities

Shineco, through its subsidiary Xi'an Dong'ao Health Management Co., Ltd., is building out its domestic service delivery. This channel relies on integrating its own facilities with partner networks.

• Integration of BICC's network with Dong'ao Health's domestic wellness channels.
• Joint establishment of stem cell transfusion centers to standardize clinical services.
• Inspection of Dong'ao Health's facilities, including its Health and Wellness Center and Cell R&D Center, by strategic partners.

Global agent network, including BICC's 3,000+ agents in Southeast Asia

The alliance with Singapore-based BICC Pte Ltd provides a massive, immediate expansion of Shineco, Inc.'s channel reach, particularly for its advanced therapies and wellness products in Asia. This network acts as extended nodes for service redemption.

The scale of this international channel is substantial:

• BICC's commercial network spans over 3,000 agents across Southeast Asia.
• This network will allow users to complete voucher verification and cell therapy services at BICC's Asian service centers.
• The agreement aims to leverage BICC's strategic presence across Asia, which includes offices in China, Thailand, and Singapore.

Direct sales channels for agricultural and healthy meal products

For its traditional agricultural and newer healthy meal segments, Shineco, Inc. relies on direct sales and significant distribution agreements. The revenue generated from these channels is a core component of the company's top line, though margins can be variable.

Here's a look at the financial scale related to these direct/product sales channels:

Metric/Event	Value/Amount	Period/Context
Revenue from Other Agricultural Products	$3,049,171	Quarterly Revenue (Q4 2024)
Distribution Agreement Value (Health Food Beverage)	Over $30 Million	Announced June 2024
Total Revenue (TTM)	$9.76M	Trailing Twelve Months (as of late 2025 data)

The company acknowledges that the cost of revenue for the quarter ending December 31, 2024, was $2,927,711, representing 96% of sales, with the higher ratio attributed to the lower gross margin of fresh fruits sold through these channels.

Shineco, Inc. (SISI) - Canvas Business Model: Customer Segments

Biotechnology and pharmaceutical companies seeking R&D services.

Shineco, Inc. core business encompasses induced pluripotent stem cell (iPSC) technology platforms and extracellular vesicle-derived products, indicating a segment focused on advanced biological research and development services.

The company's total revenue for the quarter ended December 31, 2024, was $3,049,171.

The company had a working capital deficit of $5,961,484 as of December 31, 2024.

Health and wellness consumers for cell therapy and healthy foods.

This segment is served through the Healthy Meals Products segment, which is engaged in developing and selling healthy meals for people with slow metabolic health and those in recovery from metabolic disorders.

Shineco, Inc. also produces and sells healthy and nutritious food.

Hospitals and clinics utilizing in vitro diagnostic medical devices.

Shineco, Inc. has researched and developed 33 in vitro diagnostic reagents and related medical devices to date.

The subsidiary Changzhou Biowin Pharmaceutical Co., Ltd. is engaged in the POCT (Point-of-Care Testing) business.

Biowin has 33 Chinese medical device registration certificates.

The POCT products are divided into 15 series and 45 kinds of products.

Sales Channel	Series Count	Product Kind Count
Domestic Sales	5	24
Overseas Sales	10	21

Non-U.S. institutional and accredited investors.

The financial filing discusses various financial agreements, including convertible notes and securities purchase agreements with non-U.S. investors.

The company's market capitalization as of the end of day on December 04, 2025, was $180.123K.

The company had 900,614 shares outstanding.

The company reported a gross profit of $121,460 for the quarter ended December 31, 2024.

Cash used in operating activities for the six months ended December 31, 2024, was $2,689,875.

The company's Debt / Equity ratio was 0.45.

The company's Current Ratio was 0.72.

The company's Net Cash Flow (Quarterly) for March 2025 was -$443,428.

Shineco, Inc. (SISI) - Canvas Business Model: Cost Structure

You're looking at the core expenses driving Shineco, Inc.'s operations as of late 2025. The cost structure is heavily weighted toward the cost of goods sold, but significant capital deployment is also visible in strategic technology investments and corporate maintenance.

The most immediate cost pressure comes from the core business activities. For the quarter ending December 31, 2024 (reported February 14, 2025), the Cost of Revenue was substantial, hitting $2,927,711. This represented 96% of that quarter's sales, a notable increase from 86% in the prior year's comparable quarter, which the company attributed to the lower gross margin on fresh fruits.

General overhead, while lower than the prior year, still represents a material fixed cost. In that same quarter ending December 31, 2024, General and Administrative expenses totaled $2,663,623, down from $5,591,910 previously, primarily due to a reduction in subscription receivable expenses.

Here's a quick look at some of the key reported costs and financial commitments from 2025:

Cost Category / Event	Amount / Metric	Period / Date
Cost of Revenue	$2,927,711	Quarter Ended December 31, 2024
General and Administrative Expenses	$2,663,623	Quarter Ended December 31, 2024
FuWang Acquisition Cash Outlay	$8.8 million	March 2025
Dong'ao Health R&D Contract Value	$8.7 million	Signed September 2025
FuWang Shares Issued for Acquisition	3,400,000 shares	March 2025
R&D Expense (Reported)	-$90.2k USD	Quarter Ended March 31, 2025

Shineco, Inc. has been actively investing in its future technology platforms, which translates directly into significant contractual costs. The focus is clearly on high-potential areas like induced pluripotent stem cell (iPSC) technology and microalgae research. For instance, the subsidiary Dong'ao Health signed a technology services contract in September 2025 valued at $8.7 million for the research and development of microalgae-derived extracellular vesicles technology. This contract spans from August 25, 2025, to December 31, 2026, with an initial payment of $560,000 already received.

The company also incurred substantial costs related to inorganic growth. The acquisition of a 75% equity stake in FuWang Company, a medical device specialist, finalized on March 20, 2025. This deal required a commitment of:

• Approximately US$8.8 million in cash.
• Issuance of 3,400,000 Shineco common shares.
• Transfer of the 71.42% equity interest in Dream Partner Limited.

Maintaining a public listing on Nasdaq introduces specific, non-operational costs. While a precise annual compliance budget isn't stated, the need to address listing requirements is evident. Shineco, Inc. executed a 50:1 reverse stock split, effective August 11, 2025, specifically as a measure to comply with Nasdaq Rule 5550(a)(2) regarding the minimum bid price. These actions, including legal and administrative fees associated with such corporate actions, form a recurring part of the cost base.

Shineco, Inc. (SISI) - Canvas Business Model: Revenue Streams

You're looking at the income side of Shineco, Inc. (SISI) as of late 2025, and it's clear the company is trying to pivot its revenue generation toward high-value technology and biotech contracts, though historical product sales still factor in.

The technology services contracts represent a significant near-term booking. Shineco, Inc. announced in September 2025 that its subsidiary signed a technology services contract valued at US$8.7 million with Xinke Future Biotechnology for research on microalgae-derived extracellular vesicles technology. This agreement, which runs through December 31, 2026, included an initial payment of $560,000 already received as of that announcement date. That's a concrete number you can bank on for future recognition.

Historically, and still relevant, revenue comes from product sales across a few distinct areas. The company's operations are detailed as including three main business segments:

• Rapid diagnostic and other products.
• Other agricultural products.
• Healthy meal products.

For context on product sales performance, in the quarter ending December 31, 2024, revenue increased to $3,049,171 from $2,306,902 in the same quarter the prior year, driven mainly by other agricultural products. That was a strong quarter for that segment, definitely.

Revenue from cell therapy and wellness center services is an emerging stream, supported by recent strategic moves. Following a September 2025 site visit by a Singapore-based biotechnology company delegation, the plan involves integrating networks to co-establish stem cell transfusion centers and leveraging the existing Health and Wellness Center and Cell R&D Center. Specific revenue amounts tied directly to these cell therapy or wellness center services aren't broken out in the latest public data I have access to, but the infrastructure is there to generate income.

Here's a quick look at some of the concrete financial figures we have for Shineco, Inc. revenue and related contract milestones:

Revenue/Contract Item	Amount (USD)	Date/Period Context
Technology Services Contract Value	$8,700,000	Signed September 2025
Initial Contract Payment Received	$560,000	September 2025
Q4 2024 Revenue (Product Sales)	$3,049,171	Quarter ending December 31, 2024
Annual Revenue (FY 2024)	$9.80M	Fiscal Year 2024

The most recent reported quarterly revenue figure for Shineco, Inc. is from the third quarter of 2025, which was $40.97K.